Variable expressivity of BEST1-associated autosomal dominant vitreoretinochoroidopathy (ADVIRC) in a three-generation pedigree
暂无分享,去创建一个
Rui Chen | R. Weleber | M. Vargas | M. Pennesi | Paul Yang | A. Burr | M. M. da Palma | M. E. Vargas
[1] C. Brandl,et al. Mutation-Dependent Pathomechanisms Determine the Phenotype in the Bestrophinopathies , 2020, International journal of molecular sciences.
[2] S. Tsang,et al. Investigation and Restoration of BEST1 Activity in Patient-derived RPEs with Dominant Mutations , 2019, Scientific Reports.
[3] V. Mahajan,et al. Early Onset Neovascular Inflammatory Vitreoretinopathy Due to a De Novo CAPN5 Mutation: Report of a Case , 2019, Ocular immunology and inflammation.
[4] J. Pulido,et al. A novel missense mutation in BEST1 associated with an autosomal-dominant vitreoretinochoroidopathy (ADVIRC) phenotype , 2018, Ophthalmic genetics.
[5] K. Packo,et al. Ocular Histopathology and Immunohistochemical Analysis in the Oldest Known Individual with Autosomal Dominant Vitreoretinochoroidopathy. , 2017, Ophthalmology. Retina.
[6] J. Roider,et al. Long-term changes in autosomal dominant vitreoretinochoroidopathy (ADVIRC) , 2018, Graefe's Archive for Clinical and Experimental Ophthalmology.
[7] J. Pulido,et al. Bestrophin 1 and retinal disease , 2017, Progress in Retinal and Eye Research.
[8] L. da Cruz,et al. Mislocalisation of BEST1 in iPSC-derived retinal pigment epithelial cells from a family with autosomal dominant vitreoretinochoroidopathy (ADVIRC) , 2016, Scientific Reports.
[9] Dorothy A. Thompson,et al. Unilateral BEST1-Associated Retinopathy , 2016, American journal of ophthalmology.
[10] H. Stöhr,et al. Long-Term Macular Changes in the First Proband of Autosomal Dominant Vitreoretinochoroidopathy (ADVIRC) Due to a Newly Identified Mutation in BEST1 , 2016, Ophthalmic genetics.
[11] M. Goldberg,et al. Progressive Cone Dysfunction and Geographic Atrophy of the Macula in Late Stage Autosomal Dominant Vitreoretinochoroidopathy (ADVIRC) , 2014, Ophthalmic genetics.
[12] S. Tsang,et al. BEST1: the Best Target for Gene and Cell Therapies. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[13] Michael Bach,et al. ISCEV Standard for full-field clinical electroretinography (2015 update) , 2014, Documenta Ophthalmologica.
[14] F. Torricelli,et al. BEST1 sequence variants in Italian patients with vitelliform macular dystrophy , 2012, Molecular vision.
[15] V. Sheffield,et al. Calpain-5 Mutations Cause Autoimmune Uveitis, Retinal Neovascularization, and Photoreceptor Degeneration , 2012, PLoS genetics.
[16] M. Margaglione,et al. Functional and clinical data of Best vitelliform macular dystrophy patients with mutations in the BEST1 gene , 2009, Molecular vision.
[17] B. J. Klevering,et al. The spectrum of ocular phenotypes caused by mutations in the BEST1 gene , 2009, Progress in Retinal and Eye Research.
[18] P. Campochiaro,et al. BEST1 expression in the retinal pigment epithelium is modulated by OTX family members. , 2009, Human molecular genetics.
[19] G. Holder,et al. ADVIRC is caused by distinct mutations in BEST1 that alter pre-mRNA splicing , 2008, Journal of Medical Genetics.
[20] E. Stone,et al. Differential macular and peripheral expression of bestrophin in human eyes and its implication for best disease. , 2007, Investigative ophthalmology & visual science.
[21] P. Campochiaro,et al. VMD2 Promoter Requires Two Proximal E-box Sites for Its Activity in Vivo and Is Regulated by the MITF-TFE Family* , 2007, Journal of Biological Chemistry.
[22] K. Oh,et al. Central cone dysfunction in autosomal dominant vitreoretino choroidopathy (ADVIRC). , 2006, American journal of ophthalmology.
[23] D. Baralle,et al. Mutations of VMD2 splicing regulators cause nanophthalmos and autosomal dominant vitreoretinochoroidopathy (ADVIRC). , 2004, Investigative ophthalmology & visual science.
[24] P. Campochiaro,et al. Analysis of the VMD2 Promoter and Implication of E-box Binding Factors in Its Regulation* , 2004, Journal of Biological Chemistry.
[25] A. Hutchinson,et al. Phenotype and genotype correlations in two best families. , 2003, Ophthalmology.
[26] S. Bhattacharya,et al. A clinical and molecular genetic study of a rare dominantly inherited syndrome (MRCS) comprising of microcornea, rod-cone dystrophy, cataract, and posterior staphyloma , 2003, The British journal of ophthalmology.
[27] W. Spileers,et al. Clinical and electrophysiological findings in autosomal dominant vitreoretinochoroidopathy: report of a new pedigree , 2001, Graefe's Archive for Clinical and Experimental Ophthalmology.
[28] H. Stöhr,et al. Mutations in a novel gene, VMD2, encoding a protein of unknown properties cause juvenile-onset vitelliform macular dystrophy (Best's disease). , 1998, Human molecular genetics.
[29] M. Metzker,et al. Identification of the gene responsible for Best macular dystrophy , 1998, Nature Genetics.
[30] D. Walker,et al. Molecular evidence for non-penetrance in Best's disease. , 1994, Journal of medical genetics.
[31] J. Folk,et al. Autosomal dominant neovascular inflammatory vitreoretinopathy. , 1990, Ophthalmology.
[32] G. Fishman,et al. Autosomal dominant vitreoretinochoroidopathy (ADVIRC). , 1984, The British journal of ophthalmology.
[33] G. Fishman,et al. Autosomal dominant vitreoretinochoroidopathy. , 1982, Archives of ophthalmology.
[34] R. Weleber. The effect of age on human cone and rod ganzfeld electroretinograms. , 1981, Investigative ophthalmology & visual science.